The IRMA Community
Newsletters
Research IRM
Click a keyword to search titles using our InfoSci-OnDemand powered search:
|
Neurobiology of Cannabinoids and Medical Cannabis in Therapeutic Intervention for Multiple Sclerosis: Understanding the Molecular Mechanisms of Action
|
|
Author(s): Mohammad Uzair (International Islamic University, Islamabad, Pakistan), Hammad Qaiser (Department of Biological Sciences, Faculty of Basic and Applied Sciences, International Islamic University, Islamabad, Pakistan), Muhammad Arshad (Department of Biological Sciences, Faculty of Basic and Applied Sciences, International Islamic University, Islamabad, Pakistan), Saneela Tahseen (District Headquarter Hospital, Pakistan)and Shahid Bashir (King Fahad Specialist Hospital, Dammam, Saudi Arabia)
Copyright: 2023
Pages: 30
Source title:
Medical Cannabis and the Effects of Cannabinoids on Fighting Cancer, Multiple Sclerosis, Epilepsy, Parkinson's, and Other Neurodegenerative Diseases
Source Author(s)/Editor(s): Rana R. Zeine (Kean University, USA)and Brian W. Teasdale (Kean University, USA)
DOI: 10.4018/978-1-6684-5652-1.ch008
Purchase
|
Abstract
Cannabinoids, either phytocannabinoids or synthetic derivatives of medical cannabis, exhibit a variety of potential pharmacotherapeutic effects by acting on the endocannabinoid system, through interactions with the cannabinoid receptors (CB1, CB2, and other receptors). Multiple sclerosis (MS) is an autoimmune demyelinating disease of the central nervous system (CNS) that causes spasticity, neuropathic pain, urinary bladder dysfunction, and sleep disturbance. Treatment with cannabinoids decreases the severity of disease in animal models of experimental autoimmune-Theiler's virus-induced-encephalomyelis or toxic demyelination. CBD anti-inflammatory effects decrease CNS inflammatory infiltrates, microglial activation, and cytokines IFN-γ, IL-Iβ, IL-17, or TNF-α, whereas Δ9-THC reduces spasticity. Add-on treatment with cannabinoids (Nabiximols, Sativex, equimolar concentration of THC:CBD) have demonstrated potential in alleviating the symptoms of patients with MS. This chapter reviews the evidence-based therapeutic effects of cannabinoids and their mechanisms of action relevant to MS.
Related Content
|
Kamal Smimih, Bilal El-Mansoury, Chaima Azzouhri, Youssef Ait Hamdan, Fatima Ez-zahraa Saad, Merzouki Mohamed.
© 2024.
19 pages.
|
|
Fatima Ez-Zahraa Saad, Kamal Smimih, Abdelali Bitar, Manal Khanouchi.
© 2024.
12 pages.
|
|
Samira Boulbaroud, Hanane Khalki, Fatima Zahra Azzaoui.
© 2024.
28 pages.
|
|
Bilal El-Mansoury, Kamal Smimih, Youssef Ait Hamdan, Ahmed Draoui, Samira Boulbaroud, Arumugam Radhakrishnan Jayakumar.
© 2024.
23 pages.
|
|
Kamal Smimih, Chaima Azzouhri, Fatima Ez-Zahraa Saad, Youssef Ait Hamdan, Jawad Laadraoui, Nadia Zouhairi, Mohamed Merzouki.
© 2024.
17 pages.
|
|
Himel Mondal, Shaikat Mondal.
© 2024.
20 pages.
|
|
Hafida El Ghachi, Asmaa Haj-khlifa, Mjid Oukhrib, Lahcen Tamegart, Youssef Ait Hamdan, Abdelali Ben Maloui, Najib Kissani, Halima Gamrani.
© 2024.
25 pages.
|
|
|